A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).

Motoki Yoshida,Akinori Takagane,Yasuhiro Miyake,Ken Shimada,Naoki Nagata,Atsushi Sato,Yutaka Ogata,Mutsumi Fukunaga,Koki Otsuka,Takao Takahashi,Hidetomo Matsumoto,Tatsuo Kagimura,Akihito Tsuji

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).

2016

Motoki Yoshida
Akinori Takagane
Yasuhiro Miyake
Ken Shimada
Naoki Nagata
Atsushi Sato
Yutaka Ogata
Mutsumi Fukunaga
Koki Otsuka
Takao Takahashi
Hidetomo Matsumoto
Tatsuo Kagimura
Akihito Tsuji

Objective: No salvage treatment had been established for metastatic colorectal cancer (mCRC) with mutated KRAS before the emergence of the new drugs regorafenib a

Keywords:

Bevacizumab
Phases of clinical research
Regorafenib
KRAS
Colorectal cancer
Chemotherapy
Oncology
Medicine
Internal medicine
combination chemotherapy
third line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations